Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Gross Profit: 2022-2025

Historic Gross Profit for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to $32.5 million.

  • ARS Pharmaceuticals' Gross Profit rose 1471.62% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.8 million, marking a year-over-year increase of 5395.46%. This contributed to the annual value of $89.1 million for FY2024, which is 297063.33% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Gross Profit of $32.5 million as of Q3 2025, which was up 106.79% from $15.7 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Gross Profit ranged from a high of $86.6 million in Q4 2024 and a low of $10,000 during Q2 2023.
  • Its 3-year average for Gross Profit is $18.2 million, with a median of $5.0 million in 2024.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Gross Profit plummeted by 97.84% in 2023, and later surged by 4,900.00% in 2024.
  • Quarterly analysis of 4 years shows ARS Pharmaceuticals' Gross Profit stood at $189,000 in 2022, then slumped by 97.84% to $10,000 in 2023, then skyrocketed by 4,900.00% to $86.6 million in 2024, then spiked by 1,471.62% to $32.5 million in 2025.
  • Its Gross Profit stands at $32.5 million for Q3 2025, versus $15.7 million for Q2 2025 and $8.0 million for Q1 2025.